The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis
Open accessAbstract
Several drugs approved for a variety of indications have been shown to exhibit antiangiogenic effects.Our study focuses on the PPARγ ligand rosiglitazone, a compound widely used in the treatment of type 2 diabetes.We demonstrate, for the first time to our knowledge, that PPARγ is highly expressed in tumor endothelium and is activated by rosiglitazone in cultured endothelial cells.Furthermore, we show that rosiglitazone suppresses primary tumor growth and metastasis by both direct and indirect antiangiogenic effects.Rosiglitazone inhibits bovine capillary endothelial cell but not tumor cell proliferation at low doses in vitro and decreases VEGF production by tumor cells.In our in vivo studies, rosiglitazone suppresses angiogenesis in the chick chorioallantoic membrane, in the avascular cornea, and in a variety of primary tumors.These results suggest that PPARγ ligands may be useful in treating angiogenic diseases such as cancer by inhibiting angiogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
Tontonoz, P., Hu, E., & Spiegelman, B. M. (1994) · Cell · doi:10.1016/0092-8674(94)90006-x · Cited by 3,529
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
O'Reilly, M. (1994) · Cell · doi:10.1016/0092-8674(94)90200-3 · Cited by 3,345
Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation
Liotta, L. A., Steeg, P. S., & Stetler-Stevenson, W. G. (1991) · Cell · doi:10.1016/0092-8674(91)90642-c · Cited by 2,720
The mechanisms of action of PPARs
Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Self-citationPPARγ Is Required for Placental, Cardiac, and Adipose Tissue Development
Barak, Y., Nelson, M. C., Ong, E. S., Jones, Y. Z., Ruiz-Lozano, P., Chien, K. R., Koder, A., & Evans, R. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80209-9 · Cited by 1,956
PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL
Tontonoz, P., Nagy, L., Alvarez, J. G. A., Thomazy, V. A., & Evans, R. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81575-5 · Cited by 1,797
Biological Action of Leptin as an Angiogenic Factor
Sierra-Honigmann, M. R., Nath, A. K., Murakami, C., Garcı́a-Cardeña, G., Papapetropoulos, A., Sessa, W. C., Madge, L. A., Schechner, J. S., Schwabb, M. B., Polverini, P. J., et al. (1998) · Science · doi:10.1126/science.281.5383.1683 · Cited by 1,371
Sunderkötter, C., Steinbrink, K., Goebeler, M., Bhardwaj, R., & Sorg, C. (1994) · Journal of Leukocyte Biology · doi:10.1002/jlb.55.3.410 · Cited by 1,120
Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1
Jiménez, B., Volpert, O. V., Crawford, S. E., Febbraio, M., Silverstein, R. L., & Bouck, N. (2000) · Nature Medicine · doi:10.1038/71517 · Cited by 1,020
Differentiation and reversal of malignant changes in colon cancer through PPARγ
Sarraf, P., Mueller, E., Jones, D., King, F. J., DeAngelo, D. J., Partridge, J. B., Holden, S. A., Chen, L. B., Singer, S., Fletcher, C., et al. (1998) · Nature Medicine · doi:10.1038/2030 · Cited by 988
Self-citationAbnormalities in Pericytes on Blood Vessels and Endothelial Sprouts in Tumors
Morikawa, S., Baluk, P., Kaidoh, T., Haskell, A., Jain, R. K., & McDonald, D. M. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64920-6 · Cited by 983
Terminal Differentiation of Human Breast Cancer through PPARγ
Mueller, E., Sarraf, P., Tontonoz, P., Evans, R. M., Martin, K. J., Zhang, M., Fletcher, C., Singer, S., & Spiegelman, B. M. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80047-7 · Cited by 851
Self-citationElstner, E., Müller, C., Koshizuka, K., Williamson, E. A., Park, D., Asou, H., Shintaku, P., Said, J. W., Heber, D., & Koeffler, H. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8806 · Cited by 805
Hlatky, L. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.12.883 · Cited by 787
Self-citationTontonoz, P., Singer, S., Forman, B. M., Sarraf, P., Fletcher, J. A., Fletcher, C. D. M., Brun, R. P., Mueller, E., Altiok, S., Oppenheim, H., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.1.237 · Cited by 653
Self-citationXin, X., Yang, S., Kowalski, J., & Gerritsen, M. E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.13.9116 · Cited by 513
Pasceri, V., Wu, H. D., Willerson, J. T., & Yeh, E. T. H. (2000) · Circulation · doi:10.1161/01.cir.101.3.235 · Cited by 504
Identification of an Inhibitor of Neovascularization from Cartilage
Moses, M. A., Sudhalter, J., & Langer, R. (1990) · Science · doi:10.1126/science.1694043 · Cited by 477
Self-citationMaspin is an angiogenesis inhibitor
Zhang, M., Volpert, O., Shi, Y. H., & Bouck, N. (2000) · Nature Medicine · doi:10.1038/72303 · Cited by 456
Bishop-Bailey, D., & Hla, T. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.24.17042 · Cited by 424
Elbrecht, A., Chen, Y., Cullinan, C. A., Hayes, N., Leibowitz, M. D., Moller, D. E., & Berger, J. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.1044 · Cited by 384
Hauser, S., Adelmant, G., Sarraf, P., Wright, H. M., Mueller, E., & Spiegelman, B. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001297200 · Cited by 367
Marx, N., Bourcier, T., Sukhova, G. K., Libby, P., & Plutzky, J. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.3.546 · Cited by 362
Metastatic Model for Human Prostate Cancer Using Orthotopic Implantation in Nude Mice
Stephenson, R. A., Dinney, C. P. N., Gohji, K., Ordonez, N. G., Killion, J. J., & Fidler, I. J. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.12.951 · Cited by 306
Angiogenesis-dependent diseases
FOLKMAN, J. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90021-1 · Cited by 295
Self-citationTroponin I is present in human cartilage and inhibits angiogenesis
Moses, M. A., Wiederschain, D., Wu, I., Fernandez, C. A., Ghazizadeh, V., Lane, W. S., Flynn, E., Sytkowski, A., Tao, T., & Langer, R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.2645 · Cited by 219
Self-citationRosen, K., Coll, M. L., Li, A., & Filmus, J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106424200 · Cited by 202
The Chick Embryo Chorioallantoic Membrane as a Model for in vivo Research on Anti-Angiogenesis
Ribatti, D., Vacca, A., Roncali, L., et al. (2000) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201003379040 · Cited by 135
Nakashiro, K., Hayashi, Y., Kita, A., Tamatani, T., Chlenski, A., Usuda, N., Hattori, K., Reddy, J. K., & Oyasu, R. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)61730-0 · Cited by 90
Braunhut, S. J., & Moses, M. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36856-4 · Cited by 89
Self-citationClay, C. E., Namen, A. M., Atsumi, G.-I., Trimboli, A. J., Fonteh, A. N., High, K. P., & Chilton, F. H. (2001) · Journal of Investigative Medicine · doi:10.2310/6650.2001.33786 · Cited by 67
Systemic exposure to rosiglitazone is unaltered by food
Freed, M. I., Allen, A., Jorkasky, D. K., & DiCicco, R. A. (1999) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050592 · Cited by 52
Gralinski, M., Rowse, P. E., & Breider, M. A. (1998) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199806000-00015 · Cited by 42
Research works printed but not linked: 12
- Kubota, 1998, Cancer Res, 58, 3344
- 10.1210/jc.86.5.2170 · doi:10.1210/jc.86.5.2170
- Palakurthi, 2001, Cancer Res, 61, 6213
- Murata, 2000, Invest Ophthalmol Vis Sci, 41, 2309
- Inoue, 2001, Anticancer Res, 21, 2471
- Slaton, 1999, Clin Cancer Res, 5, 2726
- Masferrer, 2000, Cancer Res, 60, 1306
- Browder, 2000, Cancer Res, 60, 1878
- Pihan, 1998, Cancer Res, 58, 3974
- Drixler, 2000, Cancer Res, 60, 1761
- 10.1172/JCI9023 · doi:10.1172/jci9023
- Fahmi, 2002, J Rheumatol, 29, 3
Cited by
Angiogenesis: an organizing principle for drug discovery?
Folkman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2115 · Cited by 2,246
Self-citationMechanisms of disease: pulmonary arterial hypertension
Schermuly, R. T., Ghofrani, H. A., Wilkins, M. R., & Grimminger, F. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.87 · Cited by 800
Angiogenesis modulates adipogenesis and obesity
Cao, Y. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32239 · Cited by 736
Antiangiogenesis in cancer therapy—endostatin and its mechanisms of action
FOLKMAN, J. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.11.015 · Cited by 658
Self-citationMarx, N., Duez, H., Fruchart, J.-C., & Staels, B. (2004) · Circulation Research · doi:10.1161/01.res.0000127122.22685.0a · Cited by 501
Metadata
- Authors
- Panigrahy, D., Singer, S., Shen, L. Q., Butterfield, C. E., Freedman, D. A., Chen, E. J., Moses, M. A., Kilroy, S., Duensing, S., Fletcher, C., Fletcher, J. A., Hlatky, L., Hahnfeldt, P., Folkman, J., & Kaipainen, A.
- Venue
- Journal of Clinical Investigation
- Published
- 2002-10-01
- Volume
- 110
- Issue
- 7
- Pages
- 923-932
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W4240908764
- Cited by
- 276
- References
- 35
- FWCI
- 5.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.